Literature DB >> 27704714

Obstetric bleeding among women with inherited bleeding disorders: a retrospective study.

L Hawke1, J Grabell1, W Sim1, L Thibeault2, E Muir1, W Hopman1, G Smith1, P James1,2.   

Abstract

INTRODUCTION: Women with inherited bleeding disorders are at increased risk for bleeding complications during pregnancy and the postpartum period, particularly postpartum haemorrhage (PPH). AIM: This retrospective study evaluates pregnancy management through the Inherited Bleeding Disorders Clinic of Southeastern Ontario, the clinical factors associated with pregnancy-related abnormal bleeding and assesses tranexamic acid use in the postpartum treatment of bleeding disorder patients.
METHODS: A chart review of 62 pregnancies, from 33 women, evaluated patient characteristics (age, haemostatic factor levels) and delivery conditions (mode of delivery, postpartum treatment) in relation to abnormal postpartum bleeding.
RESULTS: This cohort revealed increased risk of immediate PPH with increased age at delivery (mean age: 30.1 years with PPH, 26.5 years without PPH, P < 0.013), and birth by vaginal delivery (P < 0.042). Low von Willebrand factor (VWF) antigen or factor VIII (FVIII) in the third trimester was not associated with an increased risk of PPH; however, low VWF:RCo was associated with increased immediate PPH despite treatment with continuous factor infusion (P < 0.042). Women treated with tranexamic acid postpartum had less severe bleeding in the 6-week postpartum (P < 0.049) with no thrombotic complications.
CONCLUSIONS: This study contributes to the growing body of work aimed at optimizing management of bleeding disorder patients through pregnancy and the postpartum period, showing patients are at a higher risk of PPH as they age. Risk factors such as low third trimester VWF:RCo have been identified. Treatment with tranexamic acid in the postpartum period is associated with a reduced incidence of abnormal postpartum bleeding.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  antifibrinolytics; postpartum haemorrhage; pregnancy; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 27704714     DOI: 10.1111/hae.13067

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

1.  The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Hagai Amsalem; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

2.  Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Authors:  Peter A Kouides
Journal:  Blood Adv       Date:  2017-04-25

3.  Tranexamic acid to prevent post-partum haemorrhage.

Authors:  Riana Van Der Linde; Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2018-05-03       Impact factor: 3.443

4.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

5.  Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.

Authors:  Romina Brignardello-Petersen; Abdallah El Alayli; Nedaa Husainat; Mohamad A Kalot; Shaneela Shahid; Yazan Aljabirii; Alec Britt; Hani Alturkmani; Hussein El-Khechen; Shahrzad Motaghi; John Roller; Rezan Abdul-Kadir; Susie Couper; Peter Kouides; Michelle Lavin; Margareth C Ozelo; Angela Weyand; Paula D James; Nathan T Connell; Veronica H Flood; Reem A Mustafa
Journal:  Blood Adv       Date:  2022-01-11

6.  The experience of postpartum bleeding in women with inherited bleeding disorders.

Authors:  Heather VanderMeulen; Jessica Petrucci; Georgina Floros; Filomena Meffe; Katie N Dainty; Michelle Sholzberg
Journal:  Res Pract Thromb Haemost       Date:  2019-07-26

Review 7.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.